Ginkgo Bioworks (DNA) announced a collaboration with STRM.BIO and the University of British Columbia as part of the Advanced Research Projects Agency for Health’s Engineering of Immune Cell Inside the Body program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor therapies for autoimmune diseases, leveraging Ginkgo’s expertise in RNA construct design and immune cell engineering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA: